SCAI stage reclassification at 24 h predicts outcome of cardiogenic shock: Insights from the Altshock-2 registry.


Journal

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139

Informations de publication

Date de publication:
01 2023
Historique:
revised: 27 09 2022
received: 15 07 2022
accepted: 02 11 2022
pubmed: 16 11 2022
medline: 21 1 2023
entrez: 15 11 2022
Statut: ppublish

Résumé

Cardiogenic shock (CS) includes several phenotypes with heterogenous hemodynamic features. Timely prognostication is warranted to identify patients requiring treatment escalation. We explored the association of the updated Society for Cardiovascular Angiography and Interventions (SCAI) stages classification with in-hospital mortality using a prospective national registry. Between March 2020 and February 2022 the Altshock-2 Registry has included 237 patients with CS of all etiologies at 11 Italian Centers. Patients were classified according to their admission SCAI stage (assigned prospectively and independently updated according to the recently released version). In-hospital mortality was evaluated for association with both admission and 24-h SCAI stages. The overall in-hospital mortality was 38%. Of the 237 patients included and staged according to the updated SCAI classification, 20 (8%) had SCAI shock stage B, 131 (55%) SCAI stage C, 61 (26%) SCAI stage D and 25 (11%) SCAI stage E. In-hospital mortality stratified according to the SCAI classification at 24 h was 18% for patients in SCAI stage B, 27% for SCAI stage C, 63% for SCAI stage D and 100% for SCAI stage E. Both the revised SCAI stages on admission and at 24 h were associated with in-hospital mortality, but the classification potential slightly increased at 24-h. After adjusting for age, sex, lactate level, eGFR, CVP, inotropic score and mechanical circulatory support [MCS], SCAI classification at 24 h was an independent predictor of in-hospital mortality. In the Altshock-2 registry the utility of SCAI shock stages to identify risk of in-hospital mortality increased at 24 h after admission. Escalation of treatment (either pharmacological or with MCS) should be tailored to achieve prompt clinical improvement within the first 24 h after admission. Registration: http://www. gov; Unique identifier: NCT04295252.

Sections du résumé

BACKGROUND
Cardiogenic shock (CS) includes several phenotypes with heterogenous hemodynamic features. Timely prognostication is warranted to identify patients requiring treatment escalation. We explored the association of the updated Society for Cardiovascular Angiography and Interventions (SCAI) stages classification with in-hospital mortality using a prospective national registry.
METHODS
Between March 2020 and February 2022 the Altshock-2 Registry has included 237 patients with CS of all etiologies at 11 Italian Centers. Patients were classified according to their admission SCAI stage (assigned prospectively and independently updated according to the recently released version). In-hospital mortality was evaluated for association with both admission and 24-h SCAI stages.
RESULTS
The overall in-hospital mortality was 38%. Of the 237 patients included and staged according to the updated SCAI classification, 20 (8%) had SCAI shock stage B, 131 (55%) SCAI stage C, 61 (26%) SCAI stage D and 25 (11%) SCAI stage E. In-hospital mortality stratified according to the SCAI classification at 24 h was 18% for patients in SCAI stage B, 27% for SCAI stage C, 63% for SCAI stage D and 100% for SCAI stage E. Both the revised SCAI stages on admission and at 24 h were associated with in-hospital mortality, but the classification potential slightly increased at 24-h. After adjusting for age, sex, lactate level, eGFR, CVP, inotropic score and mechanical circulatory support [MCS], SCAI classification at 24 h was an independent predictor of in-hospital mortality.
CONCLUSIONS
In the Altshock-2 registry the utility of SCAI shock stages to identify risk of in-hospital mortality increased at 24 h after admission. Escalation of treatment (either pharmacological or with MCS) should be tailored to achieve prompt clinical improvement within the first 24 h after admission. Registration: http://www.
CLINICALTRIALS
gov; Unique identifier: NCT04295252.

Identifiants

pubmed: 36378673
doi: 10.1002/ccd.30484
pmc: PMC10100478
doi:

Banques de données

ClinicalTrials.gov
['NCT04295252']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

22-32

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022 The Authors. Catheterization and Cardiovascular Interventions published by Wiley Periodicals LLC.

Références

Circ Cardiovasc Qual Outcomes. 2016 Mar;9(2):117-25
pubmed: 26884615
Eur J Heart Fail. 2015 May;17(5):501-9
pubmed: 25820680
J Am Coll Cardiol. 2018 Oct 16;72(16):1972-1980
pubmed: 30309475
Catheter Cardiovasc Interv. 2020 Dec;96(7):1339-1347
pubmed: 33026155
Catheter Cardiovasc Interv. 2019 Jul 1;94(1):29-37
pubmed: 31104355
J Am Heart Assoc. 2019 Apr 16;8(8):e011991
pubmed: 30947630
Circ Cardiovasc Qual Outcomes. 2019 Mar;12(3):e005618
pubmed: 30879324
J Am Coll Cardiol. 2022 Mar 8;79(9):933-946
pubmed: 35115207
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
G Ital Cardiol (Rome). 2017 Oct;18(10):719-726
pubmed: 29105686
Circ Heart Fail. 2020 Sep;13(9):e007099
pubmed: 32900234
Catheter Cardiovasc Interv. 2023 Jan;101(1):22-32
pubmed: 36378673
J Am Heart Assoc. 2014 Jan 13;3(1):e000590
pubmed: 24419737
PLoS Med. 2007 Oct 16;4(10):e297
pubmed: 17941715
Catheter Cardiovasc Interv. 2020 Sep 1;96(3):E213-E219
pubmed: 31925996

Auteurs

Nuccia Morici (N)

IRCCS S. Maria Nascente - Fondazione Don Carlo Gnocchi ONLUS, Milan, Italy.

Simone Frea (S)

Intensive Cardiac Care Unit, Città della Salute e della Scienza di Torino, Torino, Italy.

Maurizio Bertaina (M)

Division of Cardiology, San Giovanni Bosco Hospital, ASL Città di Torino, Torino, Italy.

Alice Sacco (A)

Cardiology Department and De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Elena Corrada (E)

Humanitas Research Hospital IRCCS Rozzano, Milan, Italy.

Carlotta Sorini Dini (CS)

Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, Italy.

Martina Briani (M)

Humanitas Research Hospital IRCCS Rozzano, Milan, Italy.

Michele Tedeschi (M)

Cardiology Department, Intensive Care Unit, S. Giovanni Di Dio e Ruggi D'Aragona Hospital, Salerno, Italy.

Francesco Saia (F)

Cardiology Unit, Cardio-Thoraco-Vascular Department, University Hospital of Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.

Costanza Colombo (C)

Intensive Cardiac Care Unit, Fondazione Policlinico San Matteo Hospital IRCCS, Pavia, Italy.

Matteo Rota (M)

Department of Molecular and Translational Medicine, Units of Biostatistics and Biomathematics and Bioinformatics, University of Brescia, Brescia, Italy.

Fabrizio Oliva (F)

Cardiology Department and De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Mario Iannaccone (M)

Division of Cardiology, San Giovanni Bosco Hospital, ASL Città di Torino, Torino, Italy.

Gaetano M De Ferrari (GM)

Intensive Cardiac Care Unit, Città della Salute e della Scienza di Torino, Torino, Italy.
Department of Medical Sciences, University of Torino, Torino, Italy.

Alessandro Sionis (A)

Intensive Cardiac Care Unit, Cardiology Department, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.

Navin K Kapur (NK)

The CardioVascular Center, Tufts Medical Center, Boston, Massachusetts, USA.

Guido Tavazzi (G)

Department of Clinical-Surgical, Diagnostic and Paediatric Sciences, Unit of Anaesthesia and Intensive Care, University of Pavia Italy.
Anesthesia and Intensive Care, Fondazione Policlinico San Matteo Hospital IRCCS, Anestesia e Rianimazione I, Pavia, Italy.

Federico Pappalardo (F)

Cardiothoracic and Vascular Anesthesia and Intensive Care, AO SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH